AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a first-line treatment for breast cancer after camizestrant hit the mark in a ...
Subscribe to our weekly newsletter for the latest in industry news, expert insights, dedicated information security content and online events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results